It would be nice to see that report or even the section of that report that includes that reference. My understanding is that when AMRI's clients' drugs are approved, then that has the potential for AMRI to lock in longer term revenues and also help with capacity utilization.
At the same time, some current AMRI employees should comment here and provide some clues, if the information involved is in the public domain. I seem to remember that there used to be some comments by AMRI management about X Number of client drugs in Phase 3 etc